Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
77.48
-1.47 (-1.86%)
At close: Jan 8, 2026, 4:00 PM EST
78.00
+0.52 (0.67%)
After-hours: Jan 8, 2026, 5:58 PM EST
Apogee Therapeutics Employees
Apogee Therapeutics had 196 employees as of December 31, 2024. The number of employees increased by 105 or 115.38% compared to the previous year.
Employees
196
Change (1Y)
105
Growth (1Y)
115.38%
Revenue / Employee
n/a
Profits / Employee
-$1,294,255
Market Cap
5.23B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 196 | 105 | 115.38% |
| Dec 31, 2023 | 91 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
APGE News
- 2 days ago - Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript - Seeking Alpha
- 2 days ago - Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook - GlobeNewsWire
- 3 days ago - Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 - GlobeNewsWire
- 5 weeks ago - Apogee Therapeutics, Inc. (APGE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody - GlobeNewsWire
- 2 months ago - Apogee Therapeutics to Participate in Upcoming Conferences - GlobeNewsWire
- 3 months ago - Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million - GlobeNewsWire